• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#31 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 06 July 2011 - 11:44 PM

Mesoblast Limited (ASX:MSB) Receive FDA Clearance for Phase 3 Bone Marrow Transplant Trial
Asia Business News - 2 hours ago
Melbourne, July 7, 2011 (ABN Newswire) - Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food ...

View the full article

#32 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 10 July 2011 - 03:31 PM

Mesoblast Receives FDA Clearance for Phase 3 Bone Marrow Transplant Trial
PR-USA.net - 2 hours ago
Global regenerative medicine company Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a ...

View the full article

#33 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 15 July 2011 - 12:46 PM

BioTime Receives $335,900 SBIR Grant
Business Wire - 20 minutes ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) today announced it has been awarded a 10-month, $335,900 Small Business Innovation Research (SBIR) grant from the National ...

View the full article

sponsored ad

  • Advert

#34 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 19 July 2011 - 12:48 PM

BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent
MarketWatch - 2 hours ago
ALAMEDA, Calif., Jul 19, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -1.40% announced today the issuance of United States patent number 7,981,871 titled ...
BioTime (BTX) Receives US Patent Covering Glycosan Hydrogel Usage - StreetInsider.com

View the full article

#35 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 19 July 2011 - 12:45 PM


View the full article

#36 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 21 July 2011 - 12:48 PM

BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2011
MarketWatch - 3 hours ago
ALAMEDA, Calif., Jul 21, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +3.11% announced today that Chief Executive Officer Michael D. West, Ph.D. will present at ...

View the full article

#37 jonano

  • Guest
  • 472 posts
  • 17
  • Location:Trois-Rivieres

Posted 05 August 2011 - 12:47 AM

I invite the members of ImmInst/Longecity to be informed about my new project:

TechnoLoans: We lend money to scientists

http://technoloans.org

If we can help you, find out,

let's discuss, we treat one person per day

--Jon

#38 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 10 August 2011 - 12:49 PM

BioTime Q2 revenues rise
Pharmaceutical Business Review - 2 hours ago
BioTime, a developer of regenerative medicine, reported total revenues of $755,553 for the second quarter ended 30 June 2011, an increase of 11%, compared to $680,278 for the same period in 2010 ...

View the full article

#39 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 09 August 2011 - 10:16 PM

BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments
MarketWatch - 20 hours ago
ALAMEDA, Calif., Aug 09, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -6.71% , a biotechnology company that develops and markets products in the field of ...
BioTime Q2 Loss Widens - Quick Facts - RTT News

View the full article

#40 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 August 2011 - 03:56 PM

Wall Street Analysts Issue New Stock Ratings August 11th
Wall St. Cheat Sheet - 18 minutes ago
By Dave Friedman BioTime (AMEX:BTX): WBB Securities initiated coverage on this company with a rating of Speculative Buy and a price target of $6. About the company: BioTime, Inc. researches and ...

View the full article

#41 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 August 2011 - 02:13 PM

WBB Securities Starts BioTime, Inc. (BTX) at Speculative Buy
StreetInsider.com - 2 hours ago
StreetInsider.com provides up-to-the-minute active trading news and information. Only the most relevant news makes it through to our members, and only what you need to hear. Our articles are ...

View the full article

#42 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 August 2011 - 01:45 PM

Earnings Report Card, Regenerative Medicine Universe Edition
Seeking Alpha - 2 hours ago
An earnings release is a 'report card' of sorts for a public stem cell company. The current LPS (loss per share) standings reflect the universes' investing status. By analyzing these comparisons ...

View the full article

#43 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 August 2011 - 01:36 PM

Biotime Sees Its Net Loss Widen in Q2
Seeking Alpha - 2 hours ago
Net loss attributable to BTX for Q2/11 was $4.3M or $0.09 per share, compared to a net loss of $2.3M or $0.06 per share for Q2/10. For Q2/11, total revenue (including royalties from product sales ...

View the full article

#44 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 12 August 2011 - 12:09 PM

Nucor (NUE) (X) (ZX) (AKS) (BTX) (STLD) Get New Coverage
Everything Gold - 8 hours ago
Coverage was initiated on Nucor Co. (NYSE: NUE), US Steel (NYSE: X), China Zenix Auto International (NYSE: ZX), AK Steel Holding Co. (NYSE: AKS), BioTime Inc. (NYSE: BTX) and Steel Dynamics, Inc ...

View the full article

#45 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 August 2011 - 12:52 PM

The Short Case for Mesoblast: Little Upside Left, No Need for a Catalyst
Seeking Alpha - 3 hours ago
I've enjoyed shorting biotech stocks over the last 12 years. In the latter half of those years the companies have generally been small. They have a strange tendency to crowd in the $300 to $500 ...

View the full article

#46 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 19 August 2011 - 12:49 PM

BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines
MarketWatch - 24 minutes ago
ALAMEDA, Calif., Aug 19, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -8.65% , a biotechnology company that develops and markets products in the field of ...

View the full article

#47 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 August 2011 - 11:00 AM


View the full article

#48 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 24 August 2011 - 12:50 PM

BioTime's Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
MarketWatch - 3 hours ago
ALAMEDA, Calif., Aug 24, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -2.90% , a biotechnology company that develops and markets products in the field of ...
BioTime’s Subsidiary OncoCyte Corporation Expands Cancer Programs With $10 Million Equity Financing - TheStreet.com
BioTime’s Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing - SunHerald.com

View the full article

#49 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 25 August 2011 - 09:26 AM

6 Micro-Cap Biotech Stocks Enjoying Winning Streaks
Seeking Alpha - 10 hours ago
In the search for companies that have outperformed in a persistent way, we ran a screen on micro-cap biotech stocks (with market caps just above $100 million) for those that have seen a ...

View the full article

#50 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 September 2011 - 12:46 PM

BioTime CEO Michael D. West to Present at Rodman & Renshaw 13th Annual Healthcare Conference
MarketWatch - 22 minutes ago
ALAMEDA, Calif., Sep 01, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -9.25% , a biotechnology company that develops and markets products in the field of ...
BioTime CEO Michael D. West To Present At Rodman & Renshaw 13th Annual Healthcare Conference - TheStreet.com

View the full article

#51 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 05 September 2011 - 12:15 AM

Mesoblast Limited (ASX:MSB) Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks
ITNews - 54 minutes ago
Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase ...
Mesoblast to trial heart attack drug - Finance News Network

View the full article

#52 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 06 September 2011 - 12:47 PM

BioTime Enters into Worldwide License Agreement with Cornell University to Develop and Commercialize Vascular Cells Derived from Human Embryonic Stem Cells
MarketWatch - 2 hours ago
Technology to be utilized in product development by BioTime's subsidiaries OncoCyte Corporation and ReCyte Therapeutics, Inc. ALAMEDA, Calif., Sep 06, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes ...
BioTime Taps Cornell University Technology for hESC-Derived Vascular Cells - Genetic Engineering News
BioTime Enters Into License Agreement with Cornell (BTX) - Financial News Network Online

View the full article

#53 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 12 September 2011 - 12:47 PM

BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
MarketWatch - 2 hours ago
ALAMEDA, Calif., Sep 12, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -3.83% , a biotechnology company that develops and markets products in the field of ...
BioTime CEO Michael D. West To Present At Stem Cells USA & Regenerative Medicine Congress 2011 - TheStreet.com

View the full article

#54 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 12 September 2011 - 12:47 PM

BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
MarketWatch - 9 hours ago
ALAMEDA, Calif., Sep 12, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +1.55% , a biotechnology company that develops and markets products in the field of ...
BioTime CEO Michael D. West To Present At Stem Cells USA & Regenerative Medicine Congress 2011 - TheStreet.com

View the full article

#55 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 26 September 2011 - 03:45 PM

Mesoblast to Mass-Produce Stem-Cell Medicines in Pact With Lonza
Bloomberg - 2 hours ago
By Natasha Khan - Mon Sep 26 15:30:01 GMT 2011 Mesoblast Ltd. (MSB), the world's largest developer of stem-cell treatments, will form a manufacturing alliance with Lonza Group AG (LONN) as it ...
LONZA GROUP AG : Mesoblast and Lonza establish strategic global manufacturing alliance - 4-traders

View the full article

#56 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 26 September 2011 - 10:35 PM


View the full article

#57 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 September 2011 - 07:14 AM

Stem Cell Therapies Could Be Poised to Address the Full Gamut of Cardiovascular Disease
BiotechStockTrader.com - 1 hour ago
Regenerative medicine companies such as Athersys Inc. (NASDAQ: ATHX), Osiris Therapeutics Inc. (NASDAQ: OSIR), Mesoblast (ASX:MSB) and others are busy developing novel stem cell treatments to ...

View the full article

#58 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 September 2011 - 09:03 AM

Mesoblast and Lonza establish strategic global manufacturing alliance for stem cell products
The Pharma Letter - 10 hours ago
Australian regenerative medicine company Mesoblast (ASX: MSB) and Switzerland-based Lonza Group (SWS: LONN), a leader in biologic manufacturing, have entered into a strategic alliance for clinical ...

View the full article

#59 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 29 September 2011 - 12:48 PM

BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit
MarketWatch - 19 minutes ago
ALAMEDA, Calif., Sep 29, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -4.88% , a biotechnology company that develops and markets products in the field of ...

View the full article

#60 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 04 October 2011 - 12:46 PM

BioTime Announces Appointment of Chief Financial Officer
MarketWatch - 2 hours ago
ALAMEDA, Calif., Oct 04, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -5.44% , a biotechnology company that develops and markets products in the field of ...
BioTime (BTX) Appoints Peter Garcia as CFO - StreetInsider.com
BioTime Appoints Peter Garcia As CFO - Quick Facts - RTT News

View the full article





Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users